Welcome to LookChem.com Sign In|Join Free

CAS

  • or

103793-22-2

proglycosyn is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

103793-22-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 103793-22-2 Structure

  • Basic information

    1. Product Name: proglycosyn
    2. Synonyms: proglycosyn
    3. CAS NO:103793-22-2
    4. Molecular Formula: Br*C13H15N2O2
    5. Molecular Weight: 313.19028
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 103793-22-2.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: proglycosyn(CAS DataBase Reference)
    10. NIST Chemistry Reference: proglycosyn(103793-22-2)
    11. EPA Substance Registry System: proglycosyn(103793-22-2)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 103793-22-2(Hazardous Substances Data)

103793-22-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 103793-22-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,7,9 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 103793-22:
(8*1)+(7*0)+(6*3)+(5*7)+(4*9)+(3*3)+(2*2)+(1*2)=112
112 % 10 = 2
So 103793-22-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H15N2O2.BrH/c1-14-6-7-15(10-14)9-13(16)11-4-3-5-12(8-11)17-2;/h3-8,10H,9H2,1-2H3;1H/q+1;/p-1

103793-22-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(3-methoxyphenyl)-2-(1-methyl-1,2-dihydroimidazol-1-ium-3-yl)ethanone,bromide

1.2 Other means of identification

Product number -
Other names Proglycosyn

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:103793-22-2 SDS

103793-22-2Downstream Products

103793-22-2Related news

Effects of proglycosyn (cas 103793-22-2) (LY177507) on Fatty Acid Metabolism in Rat Hepatocytes07/17/2019

Proglycosyn (LY177507) belongs to a series of powerful agents that stabilize liver glycogen stores by promoting glycogen synthesis from different precursors and inhibiting glycogenolysis and glycolysis. In the present study we have examined the effects of proglycosyn on fatty acid metabolism in ...detailed

103793-22-2Relevant articles and documents

Method for treating fibrotic diseases or other indications with imidazolium agents

-

, (2008/06/13)

Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: wherein R1, R2, M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

Substituted imidazolium salts and their use for the inhibition of protein ageing.

-

Page 9, (2008/06/13)

The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein ageing). Accordingly, compositions are disclosed which comprise substituted imidazolium compounds capable of inhibiting the formatio

Method for treating fibrotic diseases or other indications IC

-

, (2011/07/06)

Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:

Oral Hypoglycemic Agents. Discovery and Structure-Activity Relationships of Phenacylimidazolium Halides

Dominianni, Samuel J.,Yen, Terence T.

, p. 2301 - 2306 (2007/10/02)

Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides.Compounds 2 and 3 produced reductions of ca. 40percent 2 h after doses of 100 mg/kg po.Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion.Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.

Imidazolium hypoglycemic agents

-

, (2008/06/13)

Imidazolium salts are effective in lowering blood glucose levels in mammals following administration.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 103793-22-2